PLRZ
HEALTHCAREPolyrizon Ltd
$14.34+0.20 (+1.38%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PLRZ Today?
No stock-specific AI insight has been generated for PLRZ yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.88$664.50
$14.34
Fundamentals
Market Cap$27M
P/E Ratio—
EPS$-4.90
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume13K
Avg Volume (10D)—
Shares Outstanding1.9M
PLRZ News
20 articles- Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformYahoo Finance·May 4, 2026
- Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformYahoo Finance·Apr 27, 2026
- Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsYahoo Finance·Apr 8, 2026
- Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementYahoo Finance·Apr 7, 2026
- Polyrizon Provides 2025 and Recent HighlightsYahoo Finance·Mar 26, 2026
- Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025GlobeNewswire Inc.·Mar 25, 2026
- Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility ApplicationsYahoo Finance·Mar 24, 2026
- Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development ProgramYahoo Finance·Mar 17, 2026
- Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical StudyYahoo Finance·Mar 10, 2026
- Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference ProductYahoo Finance·Feb 26, 2026
- Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy BlockerYahoo Finance·Feb 17, 2026
- Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet OperatorYahoo Finance·Feb 10, 2026
- Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen FormulationYahoo Finance·Feb 6, 2026
- Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAIYahoo Finance·Feb 6, 2026
- Polyrizon Intends to Acquire 51% Stake in Global Private Aviation CompanyYahoo Finance·Feb 4, 2026
- Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy BlockerYahoo Finance·Jan 22, 2026
- Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance SheetYahoo Finance·Jan 13, 2026
- Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™Yahoo Finance·Jan 8, 2026
- Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard ComparatorYahoo Finance·Jan 5, 2026
- As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and UnvaccinatedYahoo Finance·Jan 2, 2026
All 20 articles loaded
Price Data
Open$15.01
Previous Close$14.14
Day High$15.01
Day Low$13.85
52 Week High$664.50
52 Week Low$2.88
52-Week Range
$2.88$664.50
$14.34
Fundamentals
Market Cap$27M
P/E Ratio—
EPS$-4.90
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume13K
Avg Volume (10D)—
Shares Outstanding1.9M
About Polyrizon Ltd
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company is headquartered in Ra'anana, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—